The IL-17 expression in both CD4+CD161+ and CD4+CD161− T cells was higher in pSS patients than in healthy controls, but it did not reach statistical significance (IL-17, pSS versus HC: CD161− 2.53 ± 1.29 versus 1.86 ± 1.39, p = 0.4641; CD161+ 5.29 ± 2.37 versus 3.98 ± 2.61, p = 0.4318). The gene discussed is IL17A; the disease is peeling skin syndrome.